EUSA Pharma launches as an independent business with portfolio and name acquired from Jazz

EUSA Pharma (EUSA), a newly-established profitable specialty pharmaceutical business headquartered in Hemel Hempstead, UK, with global reach, today announced its official launch following the acquisition of five approved specialty hospital products, a multi-national commercial infrastructure and the EUSA Pharma brand name from a unit of USA-based Jazz Pharmaceuticals (Nasdaq: JAZZ).

Essex Bidco, a UK company, completed the acquisition of a number of medicines and medical devices from Jazz Pharma on March 20. As part of this acquisition, Essex Bidco also acquired the EUSA Pharma brand and will trade under this name. Financial terms of the transaction were not disclosed.

The new company is led by chief executive Bryan Morton, who has over 30 years' health care industry experience and previously founded two specialty pharmaceutical companies including the original EUSA Pharma business that was acquired by Jazz in 2012. The newly-established EUSA is supported by significant funding raised from leading health care growth equity investor Essex Woodlands, and the company has ambitious plans to accelerate its growth through acquisition and in-licensing.